Clinical Trial Update: An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD) [Phase 2]

View source ↗

Summary

The Phase 2 extension study of belcesiran for Alpha-1 Antitrypsin Deficiency-associated liver disease has been withdrawn. Sponsor: Dicerna Pharmaceuticals, Inc.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency
• Alpha-1 Antitrypsin Deficiency-associated Liver Disease

Drugs mentioned

• Belcesiran (belcesiran)

Snippet

Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Conditions: Alpha 1-Antitrypsin Deficiency | Phase 2 | Status: WITHDRAWN